IHC showed that PD-L1 was highly expressed in the BRCA/TP53 tumor tissue, showing a significant (p-value < 0.0001) difference in H-scores between PD-L1 and 2nd antibody only (Supplementary Figure S7); thus, blocking the PD-1/PD-L1 axis may be an immunotherapy strategy for this TNBC model. Here, TP53 is linked to neoplasm.